What is Sonrotoclax for CLL?

What is Sonrotoclax? 

Sonrotoclax (BGB-11417) is a second-generation B-cell lymphoma 2 inhibitor (BCL-2) created by BeiGene. It is a pill taken by mouth. CLL patients may be familiar with the first-generation BCL-2 inhibitor venetoclax (Venclexta). 

What is a BCL-2 Inhibitor?

A BCL-2 inhibitor is a type of medication designed to block the action of the B-cell lymphoma 2 protein. The BCL-2 protein is often overexpressed in certain types of cancer cells, including chronic lymphocytic leukemia (CLL). The BCL-2 protein helps regulate cell death and can contribute to cancer progression by preventing these cancerous cells from dying, a process called apoptosis. By inhibiting BCL-2, sonrotoclax promotes the death of CLL cells.

Is Sonrotoclax More Effective than Venetoclax? 

Sonrotoclax has proven to be 10 times more potent than venetoclax, meaning it works faster and more effectively in killing CLL cells, allowing patients to reach a state of undetectable minimal residual disease (uMRD), meaning there are little to no CLL cells present in the blood or bone marrow. 

Sonrotoclax also has fewer side effects than venetoclax, and it has been shown to overcome BCL-2 mutations that are often caused by prolonged venetoclax use. These improvements allow patients to reach a cancer-free state more quickly while maintaining an improved health-related quality of life during treatment. 

How Can I Receive Sonrotoclax? 

CLL specialists are administering sonrotoclax within a clinical trial in combination with the second-generation BTK inhibitor zanubrutinib, believing the regimen will be more effective together than each medicine alone. 

Click the button below to register for the clinical trial administering sonrotoclax and zanubrutinib. The study is being conducted at many locations across the United States, Australia, New Zealand, Canada, Korea, and Puerto Rico. 

If you need help signing up for the clinical trial, click the “Begin Now” button to receive assistance from HealthTree Patient Navigators.

Register for the Sonrotoclax Clinical Trial

Click here to learn more about the benefits of joining a CLL clinical trial. 

In conclusion, sonrotoclax is a second-generation BCL-2 inhibitor designed to work faster and with fewer side effects than venetoclax. The CLL community looks forward to the treatment combination of sonrotoclax and zanubrutinib as a potential new standard of CLL care in the upcoming years. 

Join the HealthTree for CLL Newsletter to Learn More! 

We invite you to click the button below to subscribe to the HealthTree for CLL newsletter and stay updated on the latest advancements in chronic lymphocytic leukemia. 

JOIN THE HEALTHTREE FOR CLL NEWSLETTER

Sources 

• Sonrotoclax
• Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy 
• Zanubrutinib + Sonrotoclax for CLL